Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The report details the trend, potential and market size of CINV Existing and Pipeline Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of CINV Existing and Pipeline Drugsmarket, defines the market attractiveness level of CINV Existing and Pipeline Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of CINV Existing and Pipeline Drugs industry, describes the types of CINV Existing and Pipeline Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global CINV Existing and Pipeline Drugs market and the development prospects and opportunities of CINV Existing and Pipeline Drugs industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global CINV Existing and Pipeline Drugs market in Chapter 13.
By Player:
Tesaro
Helsinn
Merck
Heron Therapeutics
GlaxoSmithKline
By Type:
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant
By End-User:
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 CINV Existing and Pipeline Drugs Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 CINV Existing and Pipeline Drugs Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 CINV Existing and Pipeline Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 CINV Existing and Pipeline Drugs Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise CINV Existing and Pipeline Drugs Market Analysis and Outlook to 2022
-
7.1 Global CINV Existing and Pipeline Drugs Consumption (2017-2022)
-
7.2 United States CINV Existing and Pipeline Drugs Consumption (2017-2022)
-
7.3 Europe CINV Existing and Pipeline Drugs Consumption (2017-2022)
-
7.4 China CINV Existing and Pipeline Drugs Consumption (2017-2022)
-
7.5 Japan CINV Existing and Pipeline Drugs Consumption (2017-2022)
-
7.6 India CINV Existing and Pipeline Drugs Consumption (2017-2022)
-
7.7 South Korea CINV Existing and Pipeline Drugs Consumption (2017-2022)
8 Region and Country-wise CINV Existing and Pipeline Drugs Market Analysis and Outlook to 2028
-
8.1 Global CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
-
8.2 United States CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
-
8.3 Europe CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
-
8.4 China CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
-
8.5 Japan CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
-
8.6 India CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
-
8.7 South Korea CINV Existing and Pipeline Drugs Consumption Forecast (2022-2028)
9 Global CINV Existing and Pipeline Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global CINV Existing and Pipeline Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Aloxi (palonosetron) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Zofran Generic (ondansetron) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Kytril Generic (granisetron) Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Emend (aprepitant) Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Akynzeo (netupitant-palonosetron) Consumption and Growth Rate (2017-2022)
-
9.1.6 Global SUSTOL (extended release granisetron injection) Consumption and Growth Rate (2017-2022)
-
9.1.7 Global Rolapitant Consumption and Growth Rate (2017-2022)
-
9.2 Global CINV Existing and Pipeline Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Specialty Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Diagnostic Centers Therapeutics Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Drugstores Consumption and Growth Rate (2017-2022)
10 Global CINV Existing and Pipeline Drugs Market Outlook by Types and Applications to 2028
-
10.1 Global CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Aloxi (palonosetron) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Zofran Generic (ondansetron) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Kytril Generic (granisetron) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Emend (aprepitant) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Akynzeo (netupitant-palonosetron) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global SUSTOL (extended release granisetron injection) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.7 Global Rolapitant Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Specialty Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Diagnostic Centers Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Drugstores Consumption Forecast and Growth Rate (2022-2028)
11 Global CINV Existing and Pipeline Drugs Import and Export Analysis (Top 5 Countries)
-
11.1 Global CINV Existing and Pipeline Drugs Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global CINV Existing and Pipeline Drugs Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 CINV Existing and Pipeline Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global CINV Existing and Pipeline Drugs Market Competitive Analysis
-
14.1 Tesaro
-
14.1.1 Tesaro Company Details
-
14.1.2 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Tesaro CINV Existing and Pipeline Drugs Product and Service
-
14.2 Helsinn
-
14.2.1 Helsinn Company Details
-
14.2.2 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Helsinn CINV Existing and Pipeline Drugs Product and Service
-
14.3 Merck
-
14.3.1 Merck Company Details
-
14.3.2 Merck CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Merck CINV Existing and Pipeline Drugs Product and Service
-
14.4 Heron Therapeutics
-
14.4.1 Heron Therapeutics Company Details
-
14.4.2 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Heron Therapeutics CINV Existing and Pipeline Drugs Product and Service
-
14.5 GlaxoSmithKline
-
14.5.1 GlaxoSmithKline Company Details
-
14.5.2 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of CINV Existing and Pipeline Drugs
-
Figure CINV Existing and Pipeline Drugs Picture
-
Table Global CINV Existing and Pipeline Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global CINV Existing and Pipeline Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global CINV Existing and Pipeline Drugs Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global CINV Existing and Pipeline Drugs Consumption by Country (2017-2022)
-
Figure United States CINV Existing and Pipeline Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe CINV Existing and Pipeline Drugs Consumption and Growth Rate (2017-2022)
-
Figure China CINV Existing and Pipeline Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan CINV Existing and Pipeline Drugs Consumption and Growth Rate (2017-2022)
-
Figure India CINV Existing and Pipeline Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea CINV Existing and Pipeline Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global CINV Existing and Pipeline Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure China CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea CINV Existing and Pipeline Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Aloxi (palonosetron) Consumption and Growth Rate (2017-2022)
-
Figure Global Zofran Generic (ondansetron) Consumption and Growth Rate (2017-2022)
-
Figure Global Kytril Generic (granisetron) Consumption and Growth Rate (2017-2022)
-
Figure Global Emend (aprepitant) Consumption and Growth Rate (2017-2022)
-
Figure Global Akynzeo (netupitant-palonosetron) Consumption and Growth Rate (2017-2022)
-
Figure Global SUSTOL (extended release granisetron injection) Consumption and Growth Rate (2017-2022)
-
Figure Global Rolapitant Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Specialty Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Diagnostic Centers Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Drugstores Consumption and Growth Rate (2017-2022)
-
Figure Global Aloxi (palonosetron) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Zofran Generic (ondansetron) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Kytril Generic (granisetron) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Emend (aprepitant) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Akynzeo (netupitant-palonosetron) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global SUSTOL (extended release granisetron injection) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rolapitant Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Specialty Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Diagnostic Centers Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Drugstores Consumption Forecast and Growth Rate (2022-2028)
-
Table Global CINV Existing and Pipeline Drugs Import by Region (Top 5 Countries) (2017-2028)
-
Table Global CINV Existing and Pipeline Drugs Export by Region (Top 5 Countries) (2017-2028)
-
Table Tesaro (Foundation Year, Company Profile and etc.)
-
Table Tesaro CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tesaro CINV Existing and Pipeline Drugs Product and Service
-
Table Helsinn (Foundation Year, Company Profile and etc.)
-
Table Helsinn CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Helsinn CINV Existing and Pipeline Drugs Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck CINV Existing and Pipeline Drugs Product and Service
-
Table Heron Therapeutics (Foundation Year, Company Profile and etc.)
-
Table Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Heron Therapeutics CINV Existing and Pipeline Drugs Product and Service
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline CINV Existing and Pipeline Drugs Product and Service
-
